Canton Barry has reported the sale of 18,803 shares of Ginkgo Bioworks Holdings, Inc. The shares were sold for an aggregate market value of approximately $190,711. This transaction is significant as it reflects Barry's ongoing role as an officer at Ginkgo Bioworks and highlights the active management of equity stakes by executives in the life sciences sector.
The sale occurred on October 19, 2026, and was part of a vested equity award distribution. The shares were acquired on October 16, 2026, as part of Barry's compensation package. The filing indicates that the sale includes an amount necessary to cover a tax obligation resulting from this equity award settlement.
Ginkgo Bioworks operates in the biological products sector, specifically classified under the SIC code for Biological Products (No Diagnostic Substances). This sector has seen increased activity as companies continue to innovate and expand their product offerings.
Fidelity Brokerage Services LLC facilitated the transaction. The filing does not specify any immediate next steps following this sale, but it underscores the importance of executive stock management in the life sciences industry.
Details were not available in the SEC filing regarding any potential future transactions or changes in Barry’s role at Ginkgo Bioworks.
Additional Transaction Details
The shares sold by Canton Barry were classified as Class A common stock of Ginkgo Bioworks Holdings, Inc. This transaction involved the sale of 18,803 shares, which were part of a restricted stock vesting acquired on October 16, 2026, as part of Barry's compensation package.
As of the date of the filing, Ginkgo Bioworks had a total of 55,383,808 shares outstanding. The sale was executed through Fidelity Brokerage Services LLC, which is located in Smithfield, Rhode Island. This brokerage firm acted as the intermediary for the transaction.
The filing indicates that this sale was necessary to cover tax obligations arising from the settlement of the vested equity award distribution.
Company Background
Ginkgo Bioworks is incorporated in Delaware and operates within the life sciences sector, focusing on biological products that do not include diagnostic substances. The company has been actively involved in innovation and expanding its product offerings, which aligns with the growing trends in the biotechnology industry.
Notably, the SEC filing does not provide any insights into Barry's future plans regarding his equity holdings or any potential changes in his role within Ginkgo Bioworks.